Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

被引：0
|
作者：
Makoto Ueno
Masafumi Ikeda
Takashi Sasaki
Fumio Nagashima
Nobumasa Mizuno
Satoshi Shimizu
Hiroki Ikezawa
Nozomi Hayata
Ryo Nakajima
Chigusa Morizane
机构：
[1] Kanagawa Cancer Centre Hospital,Department of Hepatobiliary and Pancreatic Oncology
[2] National Cancer Center Hospital East,undefined
[3] Cancer Institute Hospital of JFCR,undefined
[4] Kyorin University,undefined
[5] Aichi Cancer Centre Hospital,undefined
[6] Saitama Cancer Centre,undefined
[7] Eisai Co. Ltd.,undefined
[8] Eisai Inc.,undefined
[9] National Cancer Centre Hospital,undefined
来源：
BMC Cancer | / 20卷
关键词：
Lenvatinib; Biliary tract cancer; Cholangiocarcinoma; Gallbladder cancer; Ampulla of Vater;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Advancing Second-Line Treatment for Primary Biliary Cholangitis
    Assis, David N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024,
  • [22] A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study
    Yi, Jun Ho
    Thongprasert, Sumitra
    Lee, Jeeyun
    Doval, D. C.
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Kang, Won Ki
    Lim, Ho Yeong
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) : 196 - 201
  • [23] Second-line chemotherapy in patients with advanced biliary tract cancer
    Takahara, Naminatsu
    Nakai, Yousuke
    Isayama, Hiroyuki
    Sasaki, Takashi
    Ishigaki, Kazunaga
    Saito, Kei
    Mizuno, Suguru
    Kogure, Hirofumi
    Tada, Minoru
    Koike, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [24] Second-line FOLFOX chemotherapy for advanced biliary tract cancer
    Lamarca, Angela
    Palmer, Daniel H.
    Wasan, Harpreet Singh
    Ross, Paul J.
    Ma, Yuk Ting
    Arora, Arvind
    Falk, Stephen
    Gillmore, Roopinder
    Wadsley, Jonathan
    Patel, Kinnari
    Anthoney, Alan
    Maraveyas, Anthony
    Iveson, Tim
    Waters, Justin S.
    Hobbs, Claire
    Barber, Safia
    David Ryder, W.
    Ramage, John
    Davies, Linda M.
    Bridgewater, John A.
    Valle, Juan W.
    LANCET ONCOLOGY, 2021, 22 (07): : E288 - E289
  • [25] Second-line chemotherapy in patients with biliary tract cancer.
    Brandi, G.
    Di Girolamo, S.
    de Rosa, F.
    Corbelli, J.
    Agostini, V.
    Garajova, I.
    Longobardi, C.
    Paragona, M.
    Ercolani, G.
    Pinna, A. D.
    Biasco, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer
    Sasaki, Takashi
    Isayama, Hiroyuki
    Nakai, Yousuke
    Takahara, Naminatsu
    Akiyama, Dai
    Yagioka, Hiroshi
    Kogure, Hirofumi
    Matsubara, Saburo
    Ito, Yukiko
    Yamamoto, Natsuyo
    Sasahira, Naoki
    Hirano, Kenji
    Toda, Nobuo
    Tada, Minoru
    Koike, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [27] Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study
    Larsen, Finn Ole
    Markussen, Alice
    Diness, Laura V.
    Nielsen, Dorte
    ONCOLOGY, 2018, 94 (01) : 19 - 24
  • [28] An exploratory study of fruquintinib as second-line treatment for patients with advanced or metastatic biliary tract cancer.
    Li, Qiu
    Zhang, Pengfei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] A Retrospective Study of Gemcitabine and Cisplatin Combination Therapy as Second-Line Treatment for Advanced Biliary Tract Cancer
    Sasaki, Takashi
    Isayama, Hiroyuki
    Nakai, Yousuke
    Takahara, Naminatsu
    Akiyama, Dai
    Yagioka, Hiroshi
    Kogure, Hirofumi
    Matsubara, Saburo
    Ito, Yukiko
    Yamamoto, Natsuyo
    Sasahira, Naoki
    Hirano, Kenji
    Toda, Nobuo
    Tada, Minoru
    Koike, Kazuhiko
    CHEMOTHERAPY, 2013, 59 (02) : 106 - 111
  • [30] A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
    Zheng, Yi
    Tu, Xiaoxuan
    Zhao, Peng
    Jiang, Weiqin
    Liu, Lulu
    Tong, Zhou
    Zhang, Hangyu
    Yan, Cong
    Fang, Weijia
    Wang, Weilin
    BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 291 - 295
12345